+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 59 Pages
  • April 2023
  • GlobalData
  • Exelixis Inc
  • ID: 1292004
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Exelixis Inc (EXEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Exelixis Inc (Exelixis) is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company’s pipeline product candidates include zanzalintinib, XB002 and XL102 for the treatment of advanced or metastatic solid tumors and CBX-12 for advanced metastatic refractory solid tumors. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.

Exelixis Inc Key Recent Developments

  • Apr 25, 2023: Exelixis to release first quarter 2023 financial results on Tuesday, May 9, 2023
  • Jan 24, 2023: Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
  • Nov 01, 2022: Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
  • Sep 07, 2022: Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Exelixis Inc - Key Facts
  • Exelixis Inc - Key Employees
  • Exelixis Inc - Key Employee Biographies
  • Exelixis Inc - Major Products and Services
  • Exelixis Inc - History
  • Exelixis Inc - Company Statement
  • Exelixis Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Exelixis Inc - Business Description
  • Other Break-up: Collaboration Services Revenues
  • Performance
  • Other Break-up: License Revenues
  • Performance
  • Other Break-up: Net Product Revenues
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Exelixis Inc - Corporate Strategy
  • Exelixis Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Exelixis Inc - Strengths
  • Exelixis Inc - Weaknesses
  • Exelixis Inc - Opportunities
  • Exelixis Inc - Threats
  • Exelixis Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Exelixis Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 25, 2023: Exelixis to release first quarter 2023 financial results on Tuesday, May 9, 2023
  • Jan 24, 2023: Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
  • Nov 01, 2022: Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
  • Sep 07, 2022: Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
  • Aug 09, 2022: Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update
  • Apr 13, 2022: Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
  • Feb 17, 2022: Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
  • Jan 05, 2022: Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
  • Jan 04, 2022: Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Exelixis Inc, Key Facts
  • Exelixis Inc, Key Employees
  • Exelixis Inc, Key Employee Biographies
  • Exelixis Inc, Major Products and Services
  • Exelixis Inc, History
  • Exelixis Inc, Subsidiaries
  • Exelixis Inc, Key Competitors
  • Exelixis Inc, Ratios based on current share price
  • Exelixis Inc, Annual Ratios
  • Exelixis Inc, Interim Ratios
  • Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Exelixis Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Exelixis Inc, Performance Chart (2018 - 2022)
  • Exelixis Inc, Ratio Charts
  • Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Exelixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aimmune Therapeutics Inc
  • Cellectar Biosciences Inc
  • Astex Pharmaceuticals Inc
  • Novartis AG
  • Amgen Inc
  • Eloxx Pharmaceuticals Inc
  • Astex Pharmaceuticals Inc
  • Eisai Inc
  • Cellectar Biosciences Inc
  • Aimmune Therapeutics Inc
  • Novartis AG
  • Amgen Inc
  • Eisai Inc
  • Eloxx Pharmaceuticals Inc